Comparison of 68Ga-FAPI-04 and 68Ga-PSMA in a Case of Interstitial Lung Disease

Hasan Önner; Abidin Kılınçer

doi:10.4274/mirt.galenos.2024.93270

Abstract

We present the ⁶⁸Ga-prostate-specific membrane antigen (PSMA) and ⁶⁸Ga-fibroblast activation protein inhibitor (FAPI)-04 positron emission tomography/computed tomography (PET/CT) findings comparatively of a 76-year-old man with a history of progressive dyspnea and evidence of interstitial lung disease (ILD) abnormalities on high-resolution CT. Moderate PSMA uptake was observed in areas with ILD abnormalities on ⁶⁸Ga-PSMA PET/CT. ⁶⁸Ga-FAPI-04 PET/CT showed relatively higher FAPI-04 uptake in these regions. These findings offer the potential to assess disease activity at the cellular and molecular levels. This approach may provide valuable insight into the pathophysiology of ILD beyond the structural changes captured by traditional imaging methods.

Keywords:

Fibroblast activation protein inhibitor, interstitial lung disease, PSMA, PET

Figure 1

Ethics

Informed Consent: The patient provided written informed consent.

Authorship Contributions

Surgical and Medical Practices: H.Ö., A.K., Concept: H.Ö., A.K., Design: H.Ö., A.K., Data Collection or Processing: H.Ö., A.K., Analysis or Interpretation: H.Ö., A.K., Literature Search: H.Ö., A.K., Writing: H.Ö., A.K.

Conflict of Interest: No conflicts of interest were declared by the authors.

Financial Disclosure: The authors declare that this study has received no financial support.

References

Mendes RG, Castello-Simões V, Trimer R, Garcia-Araújo AS, Gonçalves Da Silva AL, Dixit S, Di Lorenzo VAP, Archiza B, Borghi-Silva A. Exercise-Based Pulmonary Rehabilitation for Interstitial Lung Diseases: A Review of Components, Prescription, Efficacy, and Safety. Front Rehabil Sci. 2021;2:744102.

CrossRef PubMed Google Scholar

Rodriguez K, Ashby CL, Varela VR, Sharma A. High-Resolution Computed Tomography of Fibrotic Interstitial Lung Disease. Semin Respir Crit Care Med. 2022;43:764-779.

CrossRef PubMed Google Scholar

de Galiza Barbosa F, Queiroz MA, Nunes RF, Costa LB, Zaniboni EC, Marin JFG, Cerri GG, Buchpiguel CA. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. Cancer Imaging. 2020;20:23.

CrossRef PubMed Google Scholar

Rosenkrans ZT, Massey CF, Bernau K, Ferreira CA, Jeffery JJ, Schulte JJ, Moore M, Valla F, Batterton JM, Drake CR, McMillan AB, Sandbo N, Pirasteh A, Hernandez R. [(68) Ga]Ga-FAPI-46 PET for non-invasive detection of pulmonary fibrosis disease activity. Eur J Nucl Med Mol Imaging. 2022;49:3705-3716.

CrossRef PubMed Google Scholar

Dendl K, Koerber SA, Kratochwil C, Cardinale J, Finck R, Dabir M, Novruzov E, Watabe T, Kramer V, Choyke PL, Haberkorn U, Giesel FL. FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis? Cancers (Basel). 2021;13:4946.

CrossRef

Yang P, Luo Q, Wang X, Fang Q, Fu Z, Li J, Lai Y, Chen X, Xu X, Peng X, Hu K, Nie X, Liu S, Zhang J, Li J, Shen C, Gu Y, Liu J, Chen J, Zhong N, Su J. Comprehensive Analysis of Fibroblast Activation Protein Expression in Interstitial Lung Diseases. Am J Respir Crit Care Med. 2023;207:160-172.

Sviridenko A, di Santo G, Virgolini I. Imaging Fibrosis. PET Clin. 2023;18:381-388.

CrossRef PubMed Google Scholar

Mori Y, Kramer V, Novruzov E, Mamlins E, Röhrich M, Fernández R, Amaral H, Soza-Ried C, Monje B, Sabbagh E, Florenzano M, Giesel FL, Undurraga Á. Initial results with [(18)F]FAPI-74 PET/CT in idiopathic pulmonary fibrosis. Eur J Nucl Med Mol Imaging. 2024;51:1605-1611.

Röhrich M, Leitz D, Glatting FM, Wefers AK, Weinheimer O, Flechsig P, Kahn N, Mall MA, Giesel FL, Kratochwil C, Huber PE, Deimling AV, Heußel CP, Kauczor HU, Kreuter M, Haberkorn U. Fibroblast Activation Protein-Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study. J Nucl Med. 2022;63:127-133.

CrossRef PubMed Google Scholar